Vanguard Capital Management
CTMX icon

Vanguard Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Vanguard Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32M Sell
8,525,457
-207,661
-2% -$793K ﹤0.01% 2174
2026
Q1 		$41M Buy
+8,733,118
New +$44.3M ﹤0.01% 1964

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management's CTMX Position: Q2 2026 in Review

Vanguard Capital Management reduced its CytomX Therapeutics (CTMX) stake by 2.4% in Q2 2026, selling an estimated $793K and leaving 8,525,457 shares worth $32M. The position accounts for ﹤0.01% of the portfolio, ranked #2174.

Vanguard Capital Management first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $41M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Vanguard Capital Management held 8,525,457 shares of CytomX Therapeutics worth $32M as of Q2 2026.
  • Vanguard Capital Management sold 207,661 CytomX Therapeutics shares in Q2 2026, an estimated $793K.
  • CytomX Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2174 holding.
  • Vanguard Capital Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's CytomX Therapeutics position peaked at $41M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.